A Phase 2 interventional study of Oglemilast and Placebo then Oglemilast in Asthma, sponsored by Forest Laboratories. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2012-03-20.
Sponsored by Forest Laboratories · Phase 2, Interventional, and Prevention
The purpose of this study is to determine whether oglemilast is safe and effective in the treatment of allergen-induced asthma.
3,921 studies on the registry are indexed under Asthma; 507 are open to participants now.
This study's enrollment of 6 is below the median of 83 across 2,752 interventional studies indexed under Asthma.
Browse Asthma studies →Forest Laboratories is the lead sponsor of 165 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Oglemilast
Drug: Placebo then Oglemilast
Oglemilast, 15mg oral administration, once per day and then dose-matched placebo
Dose-matched placebo and then Oglemilast, 15mg, oral administration, once per day.
To determine the effect of oglemilast in the prevention of bronchoconstriction after the administration of allergen, in comparison with placebo in patients with mild asthma
Time frame: From Baseline to Day 7
To evaluate the safety of oglemilast over 2 weeks as determined by adverse events,physical examinations, vital signs, electrocardiograms, and laboratory examinations
Time frame: From Baseline to Day 14
This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Forest Laboratories